Anwaar Saeed
Clinical trials sponsored by Anwaar Saeed, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Triple-Drug attack on liver cancer shows promise in early trial Results expected Dec 2026 (estimated)
-
New combo therapy aims to boost immune attack on hard-to-treat GI cancers
Disease control Recruiting nowThis study tests whether combining the targeted drug cabozantinib with immunotherapy drugs (durvalumab, with or without tremelimumab) is safe and effective for people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that c…
Phase 1/2 • Sponsor: Anwaar Saeed • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Triple-Drug attack on liver cancer shows promise in early trial
Disease control Recruiting nowThis Phase 2 trial is testing whether a combination of three drugs—zanzalintinib, durvalumab, and tremelimumab—can shrink tumors in people with advanced liver cancer that cannot be removed surgically. The study will enroll 40 participants who have not received prior systemic ther…
Phase 2 • Sponsor: Anwaar Saeed • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New cocktail targets tough pancreatic cancer in early trial
Disease control Recruiting nowThis early-phase study tests a three-part drug combination for people with advanced pancreatic cancer who haven't had chemotherapy yet. The drugs include elraglusib (a targeted agent), retifanlimab (an immunotherapy), and a standard chemo regimen called mFOLFIRINOX. The main goal…
Phase 1 • Sponsor: Anwaar Saeed • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC